

MOLST Legal Requirements Checklist For People With Developmental Disabilities

Ī	AST NAME/FIRST NAME DATE OF BIRTH
_	ADDRESS
this chec their own withholdi and do no	actual orders should be placed on the MOLST form with this completed checklist attached. Use of klist is required for individuals with developmental disabilities (DD) who lack the capacity to make a health care decisions and do not have a health care proxy. Medical decisions which involve the ng or withdrawing of life sustaining treatment (LST) for individuals with DD who lack capacity of have a health care proxy must comply with the process set forth in the Health Care Decisions Act ons with MR (HCDA) [SCPA § 1750-b (4)]. Effective June 1, 2010, this includes the issuance of lers.
	Identification of Appropriate 1750-b Surrogate from Prioritized List. Check appropriate category name of surrogate.
	a. 17-A guardian b. actively involved spouse c. actively involved parent d. actively involved adult child e. actively involved adult sibling f. actively involved family member g. Willowbrook CAB (full representation) h. Surrogate Decision Making Committee (MHL Article 80)
regarding	- 1750-b surrogate has a conversation or a series of conversations with the treating physician possible treatment options and goals for care. Following these discussions, the 1750-b surrogate decision to withhold or withdraw LST, either orally or in writing.
Specify t	the LST that is requested to be withdrawn or withheld:
1	Decision made orally
Witness -	- Attending Physician Second Witness
attending	Decision made in writing (must be dated, signed by surrogate, signed by 1 witness and given to g physician).

Revised March 2020 Page 1

LAST NAME/FIRST NAME	DATE OF BIRTH
or the concurring physician or licensed employed for at least 2 years in a facil	capacity to make health care decisions. Either the attending physician psychologist must: (a) be employed by a DDSO; or (b) have been lity or program operated, licensed or authorized by OPWDD; or (c) oner of OPWDD as either possessing specialized training or have 3 to individuals with DD.
Attending Physician	Concurring Physician or Licensed Psychologist
Step 4– Determination of Necessary Me	edical Criteria.
We have determined to a reasonable dimet:	legree of medical certainty that both of the following conditions are
(1) the individual has one of the following	ng medical conditions:
a. a terminal condition; (briefly	y describe
);
	s; or nan DD which requires LST, is irreversible and which will continue be
)
(2) the LST would impose an extraording a. the person's medical condition	AND ary burden on the individual in light of: other than DD (briefly explain
) and
b. the expected outcome of the L	ST, notwithstanding the person's DD (briefly explain
If the 1750-b surrogate has requ withheld, one of the following additional	nested that artificially provided nutrition or hydration be withdrawn or
a. there is no reasonable hope of	maintaining life (explain
b. the artificially provided nutrit	ion or hydration poses an extraordinary burden (explain:
)
Attending Physician	Concurring Physician

Revised March 2020 Page 2

LAST NAME/FIRST NAME DATE OF BIRTH
LAST NAIVIETTEST NAIVIE DATE OF BIRTH
Step 5 – Notifications. At least 48 hours prior to the implementation of a decision to withdraw LST, or a the earliest possible time prior to a decision to withhold LST, the attending physician must notify the following parties:
the person with DD, unless therapeutic exception applies
notified on/
if the person is in or was transferred from an OPWDD residential facility
Facility Director notified on//
MHLS notified on/
if the person is not in and was not transferred from an OPWDD residential facility
the director of the local DDSO notified on//
Step 6 - I certify that the 1750-b process has been complied with, the appropriate parties have been notified and no objection to the surrogate's decision remains unresolved.
Attending Physician Date

Note: The MOLST form may ONLY be completed with the 1750-b surrogate after all 6 steps on this checklist have been completed.

Revised March 2020 Page 3